Septerna to Present at Jefferies Global Healthcare Conference
Septerna (NASDAQ: SEPN), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO and Co-founder, Jeffrey Finer, M.D., Ph.D., will deliver a presentation on Thursday, June 5, 2025, at 3:45 p.m. ET in New York. Interested parties can access a live webcast of the presentation through the company's website or the provided link, with the recording remaining available for at least 30 days afterward.
Septerna (NASDAQ: SEPN), un'azienda biotecnologica specializzata nella scoperta di farmaci mirati ai recettori accoppiati a proteine G (GPCR), ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il CEO e cofondatore dell'azienda, Jeffrey Finer, M.D., Ph.D., terrà una presentazione il giovedì 5 giugno 2025 alle 15:45 ET a New York. Gli interessati potranno seguire la diretta streaming della presentazione tramite il sito web dell'azienda o il link fornito, con la registrazione disponibile per almeno 30 giorni successivi.
Septerna (NASDAQ: SEPN), una empresa biotecnológica enfocada en el descubrimiento de fármacos dirigidos a los receptores acoplados a proteínas G (GPCR), ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El CEO y cofundador de la compañía, Jeffrey Finer, M.D., Ph.D., realizará una presentación el jueves 5 de junio de 2025 a las 3:45 p.m. ET en Nueva York. Los interesados podrán acceder a una transmisión en vivo a través del sitio web de la empresa o mediante el enlace proporcionado, con la grabación disponible durante al menos 30 días después.
Septerna (NASDAQ: SEPN)는 G 단백질 연결 수용체(GPCR) 약물 발견에 중점을 둔 생명공학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 CEO이자 공동 창립자인 Jeffrey Finer, M.D., Ph.D.가 2025년 6월 5일 목요일 오후 3시 45분(동부 표준시) 뉴욕에서 발표를 진행할 예정입니다. 관심 있는 분들은 회사 웹사이트 또는 제공된 링크를 통해 발표 실시간 웹캐스트를 시청할 수 있으며, 녹화 영상은 최소 30일간 다시보기로 제공됩니다.
Septerna (NASDAQ : SEPN), une société de biotechnologie spécialisée dans la découverte de médicaments ciblant les récepteurs couplés aux protéines G (GPCR), a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le PDG et cofondateur de l'entreprise, Jeffrey Finer, M.D., Ph.D., présentera une intervention le jeudi 5 juin 2025 à 15h45 (heure de l'Est) à New York. Les personnes intéressées pourront suivre la présentation en direct via le site web de la société ou le lien fourni, avec un enregistrement disponible pendant au moins 30 jours après la diffusion.
Septerna (NASDAQ: SEPN), ein Biotechnologieunternehmen, das sich auf die Entdeckung von Wirkstoffen gegen G-Protein-gekoppelte Rezeptoren (GPCR) spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Der CEO und Mitbegründer des Unternehmens, Jeffrey Finer, M.D., Ph.D., wird am Donnerstag, den 5. Juni 2025, um 15:45 Uhr ET in New York eine Präsentation halten. Interessierte können die Präsentation live über die Unternehmenswebseite oder den bereitgestellten Link verfolgen; die Aufzeichnung steht mindestens 30 Tage danach zur Verfügung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York.
A live webcast of the presentation will be available here and in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Septerna (SEPN) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Septerna (SEPN) at the Jefferies Healthcare Conference 2025?
How can investors watch Septerna's (SEPN) presentation at the Jefferies Conference?
What is Septerna's (SEPN) main business focus?
